HER-2阳性乳腺癌新辅助治疗腋窝病理完全缓解的预测因素分析  

Predictive factors of axillary pathological complete response in neoadjuvant-treated HER-2-positive breast cancer

作　　者：刘世伟 张蒲蓉 曾石岩 牟鳄贤 张欣 徐佳 李卉 张剑辉 LIU Shiwei;ZHANG Purong;ZENG Shiyan;MOU Exian;ZHANG Xin;XU Jia;LI Hui;ZHANG Jianhui(Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology of China,Sichuan Chengdu 610041,China)

机构地区：[1]四川省肿瘤医院·研究所,四川省癌症防治中心,电子科技大学医学院,四川成都610041

出　　处：《现代肿瘤医学》2021年第3期410-413,共4页Journal of Modern Oncology

摘　　要：目的:研究人类表皮生长因子受体2(human epidermal growth factor receptor 2,HER-2)阳性乳腺癌新辅助治疗腋窝病理完全缓解(axillary pathological complete response,apCR)的预测因素。方法:回顾性分析2017年1月至2019年12月四川省肿瘤医院乳腺外科中心经治的新辅助治疗HER-2阳性乳腺癌,分析临床病理特点与apCR的相关性。统计学分析使用SPSS 22.0统计学软件。计量资料使用最小值、最大值和中位数表示,计数和等级资料使用频数和百分比表示。单因素分析使用χ~2检验或Fisher确切概率法,多因素分析使用二元Logistic回归分析。结果:本研究纳入94例HER-2阳性乳腺癌,总体apCR率为73.4%(69/94)。单因素分析显示,临床N_0期(P=0.005)、激素受体状态阴性(P=0.008)、联合抗HER-2治疗(P<0.001)及达到乳房病理完全缓解(P=0.007)与高apCR率的相关性具有统计学意义。多因素分析显示,联合抗HER-2治疗(OR=4.77,95%CI:1.49~15.34,P=0.009)是高apCR率的独立预测因素。结论:联合抗HER-2治疗是HER-2阳性乳腺癌新辅助治疗apCR的独立预测因素。Objective:To investigate the predictive factors of axillary pathological complete response(apCR)in human epidermal growth factor receptor 2(HER-2)-positive breast cancer treated with neoadjuvant treatment(NAT).Methods:Data of HER-2-positive breast cancer treated with NAT and radical surgery in the Breast Surgery Center of Sichuan Cancer Hospital from January 2017 to December 2019 was retrospectively reviewed.The Chi-square test or Fisher's exact test was conducted for univariate analyses,and Logistic regression analyses were performed for multivariate analyses.Statistical analyses were conducted using SPSS version 22.0.Results:Ninety-four HER-2-positive patients were included,and the overall apCR rate was 73.4%(69/94).Clinical N 0 stage(P=0.005),negative status of hormone receptor(P=0.008),anti-HER-2 therapy(P<0.001)and breast pathological complete response(P=0.007)were significantly associated with apCR in univariate analysis.Anti-HER-2 therapy(OR=4.77,95%CI:1.49~15.34,P=0.009)was independently associated with apCR in multivariate analysis.Conclusion:Anti-HER-2 therapy was an independent predictive factor for apCR in neoadjuvant-treated HER-2-positive breast cancer.

关 键 词：乳腺癌 人类表皮生长因子受体2 新辅助治疗 腋窝病理完全缓解 预测因素 

分 类 号：R737.9[医药卫生—肿瘤]